Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib and TACE in TACE-refractory HCC
NCT03510416Phase 2Unknown
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- May 2018
- Primary completion
- Jun 2019
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in hepatocellular carcinoma (HCC), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Time To Progression at 14 months. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03510416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03510416.